Launch list prices for prescription drugs approved by U.S. regulators in 2025 decreased from 2024 levels but remained substantial, with a median of $216,000, an analysis shows. While lower than last year’s median, the figure reflects the continued prominence of high-priced treatments for rare and complex diseases.
Historical medians cited in the analysis place 2024 above $370,000, 2023 at $300,000 and 2022 at $222,000. Experts who reviewed the 2025 data said the change is attributable primarily to differences in the types of products the Food and Drug Administration approved rather than to a widespread shift in how companies set prices or to any lasting government policy change aimed at reducing launch prices.
One factor highlighted by analysts is the relative decline in approvals for cell and gene therapies, which are often administered as a single treatment and can carry prices in the millions of dollars. The FDA approved five cell and gene therapies in 2025, compared with seven in each of 2024 and 2023. Those single-administration therapies have a disproportionate effect on median pricing when they are present in larger numbers among approvals.
At the same time, more than 67% of FDA approvals in 2025 were for small-molecule drugs, such as pills manufactured from chemical processes, a higher share than the 62% in 2024 and 57% in 2023. Small molecules generally have lower development and production complexity compared with biologics derived from living cells, and their greater representation depresses the overall median list price for the year.
Yet despite the lower median, the average launch price for 2025 approvals remained high at $416,000. The distribution of listed prices in 2025 encompassed very low-cost launches alongside extremely costly treatments. For example, the analysis notes $1,050 list pricing for Vizz eye drops from LENZ Therapeutics and $5,400 for Lerochol, a cholesterol drug from LIB Therapeutics. Those lower-priced entries offset medicines listed at much higher price points, such as Forzinity from Mighty Therapeutics for Barth syndrome, with a list price near $800,000 per year.
How stakeholders interpret the shift
Trade group Pharmaceutical Research and Manufacturers of America said it is misleading to compare prices for new therapies that address serious, complex conditions with limited or no alternatives to prices for other types of drugs. That perspective underscores the argument from industry that the clinical value and scarcity of treatment options justify premium pricing in many cases.
Independent observers point to market structure and product novelty as drivers of high launch prices. Richard Frank, director at the Brookings Institution’s Center on Health Policy, said new biologics are often first-in-class and face little or no competition at launch, which permits manufacturers to set elevated prices.
Politics, agency operations and pricing dynamics
Observers caution that 2025 was an unusual year at the FDA. Dr. Benjamin Rome, an assistant professor at Harvard Medical School who studies drug pricing, said it is difficult to draw broad conclusions from a single year and called 2025 an odd year. He noted that the agency experienced organizational pressure tied to reorganization efforts under the Trump administration, including staff reductions and leadership turnover. Those changes coincided with several rejections of gene therapy applications, which triggered pushback from patient advocates and political controversy. Earlier in the year, the FDA indicated it would adopt a more flexible regulatory posture.
Political pressure on drugmakers is also a factor in public discussion. The Trump administration has promoted policies such as the TrumpRx platform for direct-to-consumer sales and reached pricing agreements intended to align some U.S. prices with those in other developed nations. Brookings’ Frank said those agreements are unlikely to persist beyond the current administration. Rome added that in the absence of legislation, such deals are unlikely to produce lasting effects on manufacturers’ pricing decisions.
Geoffrey Joyce, director at the University of Southern California’s Schaeffer Center for Health Policy and Economics, characterized much of the public-facing effort to lower prices as performative. He said there has been a trend of announcing measures aimed at lowering drug costs that may not translate into meaningful, durable changes.
Composition of approvals and commercial implications
The FDA approved 51 new drugs in 2025, including 46 approvals at its main review division and the five cell and gene therapies. Those totals compare with 57 approvals in 2024 and 55 in 2023. The counts exclude imaging agents, blood testing reagents and vaccines. The pricing analysis itself examined list prices for 42 drugs compiled by 3 Axis Advisors and intentionally excluded products used intermittently, such as antibiotics, and drugs that have not yet launched commercially.
Cancer therapies continued to represent the largest therapeutic category in 2025 approvals, accounting for roughly one third of the new drug approvals. More than half of the approved drugs were designated orphan products, intended to treat conditions affecting fewer than 200,000 Americans. Orphan incentives, which include extended market exclusivity and other benefits, are intended to encourage research into rare diseases but can also support premium pricing for niche products.
Joyce warned that manufacturers can exploit orphan incentives by seeking approval for a low-prevalence indication even when a drug may be effective in a broader set of conditions, thereby obtaining regulatory and tax advantages. He said the commercial logic often is to launch at the highest price the market will bear.
Pricing measures and the limits of list prices
Industry representatives emphasize that new medicines can deliver downstream cost offsets, such as fewer emergency room visits and reduced hospitalizations, which can factor into value assessments. The analysis reviewed only list prices and did not account for undisclosed discounts and rebates that insurers and payers may secure from manufacturers.
Dr. Rome cautioned that, factoring in those list prices, many new drugs still command very high costs at launch. He noted, "You’re still paying hundreds of thousands of dollars for most new drugs... irrespective of whether they offer a huge benefit over existing drugs or are sort of novel products that don’t offer much benefit."
Market participants and policymakers will continue to watch whether the mix of approvals reverts to prior patterns or whether regulatory and political developments produce more durable changes in how manufacturers price newly launched therapies.